Exelixis Climbs 21% on Positive Phase 3 Advanced Kidney Cancer Study Results: https://t.co/vcbQPsDEn7

Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial.

$EXEL #cancer #healthcare #stocks https://t.co/TwCsT0Nzhz